12 results
8-K
EX-2.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
10 Aug 21
Maravai Lifesciences Reports Second Quarter Financial Results and Updates 2021 Financial Guidance
4:18pm
, contaminant or toxic substance under, or for which Liability or standards of care are imposed by, any Environmental Law.
(bv)“HIPAA” means collectively: (i
10-K
2020 FY
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
22 Mar 21
Annual report
4:22pm
Technologies product categories include HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents and custom services … % of our Biologics Safety Testing revenue in the year ended December 31, 2020.
Other impurity and contaminant kits. Products in this category include
424B4
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
23 Nov 20
Prospectus supplement with pricing info
4:36pm
bioprocess impurity and contaminant ELISA kits, ancillary reagents and custom services.
HCP ELISA kits. HCP ELISAs are kits used to detect residual … , 2020.
Other impurity and contaminant kits. Products in this category include kits for measuring Protein A leachate, which results from the affinity
S-1/A
EX-10.26
u2qf55a25h 998fcn
9 Nov 20
IPO registration (amended)
2:05pm
S-1
EX-10.16
7puwt8fb1cxdmd4dwr
29 Oct 20
IPO registration
5:04pm
S-1
fpd79aa
29 Oct 20
IPO registration
5:04pm
DRS/A
2bem91f3 jvn4z0
23 Oct 20
Draft registration statement (amended)
12:00am
DRS/A
sd1xgvp5 etq
14 Oct 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.16
57jh4rjnlk e2u
14 Oct 20
Draft registration statement (amended)
12:00am
DRS
jnys187d
8 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next